Skip to main content

Table 2 Clinical trials have been conducted targeting various parts of MCL pathophysiology

From: Mantle cell lymphoma and its management: where are we now?

Target

Study

Setting

Phase

Regimen

ORR

CR

PFS

OS

1

Proteasome inhibitor

Fisher et al. [33]

Relapsed

I/II

V

33%

8%

NA

NA

Ruan et al. [34]

Front line

I/II

V + RCHOP

91%

64%

23 months

NR

Till BG et al. [36]

Front line

II

V + RCHOP

83%

57%

29.5 months

NR

Chang et al. [37]

Front line

II

V + Modified R-HyperCVAD (VcR-CVAD) and MR for 5 years

90%

77%

8.14 years

NR

2

Bruton’s tyrosine kinase inhibitor

Rule et al. [40]

Relapsed/refractory

PA

Ibrutinib monotherapy

69.7%

26.5%

13 months

26.7 months

Wang et al. [41]

Relapsed/refractory

II

Ibrutinib + R

88%

44%

75% (12 months)

85.5% (12 months)

Maddocks et al. [42]

Relapsed or new MCL

I/Ib

Ibrutinib + BR

94%

76%

NA

NA

Wang et al. [44]

Relapsed

II

Acalabrutinib

81%

40%

67% (12 months)

87% (12 months)

Walter et al. [45]

Relapsed

I

ONO/GS-4059

92%

46%

NA

NA

Tam et al. [46]

Relapsed

II

Ibrutinib+venetoclax

71%

62%

NA

NA

3

Epigenetic agents

Pu et al. [48]

New or relapsed/refractory MCL

I/II

Cladribine + R + V

85%

77%

NR

NR

Spurgeon et al. [47]

New or relapsed MCL, CLL, NHL

II

Vorinostat + Cladribine + R

97% (untreated MCL)

80% (untreated MCL)

70.7% (24 months)

86% (24 months)

Puvvada et al. [49]

New or relapsed MCL and indolent NHL

II

Cladribine + R + V

100%

50%

82% (24 months)

91% (24 months)

4

Immunomodulatory agent

Goy et al. [50]

Relapsed

II

Len monotherapy

28%

7.5%

4 mon

19 mon

Habermann et al. [51]

Relapsed

II

Len monotherapy

53%

20%

5.6 mon

NA

Witzig et al. [52]

Relapsed

II

Len monotherapy

42%

21%

5.7 mon

NA

Wang et al. [54]

Relapsed/refractory

I/II

Len + R

57%

36%

11.1 mon

24.3 months

Ruan et al. [55, 56]

First line

II

Len + R

92%

64%

Not reached

97% (2 years OS)

Morrison et al. [53]

Relapsed/refractory

II

Len + V

39.6%

15.1%

7 months

26 months

Albertsson-Lindblad et al. [57]

First line

I/II

Len + BR

91%

78%

42 months

53 months

5

mTOR kinase inhibitors

Hess et al. [58]

Relapsed/refractory

III

Temsirolimus vs. investigator’s choice

6–22%

0–2%

4.8–3.4 months

12.8–10 months

Witzig et al. [59]

Relapsed

II

Temsirolimus monotherapy

30%

3%

6.5 months

12 months

Ansell et al. [60]

Relapsed

II

Temsirolimus monotherapy

41%

3.7%

6 months

NA

Wang et al. [62]

Refractory to V

II

Everolimus monotherapy

8.6%

0%

4.4 months

16.9 months

Hess et al. [61]

Relapsed

I

Temsirolimus + BR

92%

45%

NA

NA

6

CART and BiTE

Abramson et al. [66]

Relapse/refractory

Pivotal trial

Lisocabtagene maraleucel (JCAR017)

72% (NHL)

52% (NHL)

NA

NA

ZUMA-2 [68]

Relapsed/refractory

II

Axicabtagene ciloleucel

NA

NA

NA

NA

Goebeler et al. [69]

Relapsed/refractory

I

Blinatumomab

71%

NA

NA

NA

Dufner et al. [70]

Relapsed/refractory

I

Blinatumomab

NA

NA

204 days

1560 days

Budde et al. [71]

Relapsed/refractory

I

Mosunetuzumab

41%

NA

NA

NA

  1. V Bortezomib; R rituximab; RCHOP rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; R-HyperCVAD rituximab, hyperfractionated cytarabine, vincristine, doxorubicin and dexamethasone; MR maintenance rituximab; BR Bendamustine and rituximab; Len Lenalidomide; CART Chimeric antigen receptor-engineered T-cells; BiTE Bi-specific T-cells Engager; NA not available; NR not reached; PA pooled analysis